FI79103B - Foerfarande foer framstaellning av terapeutiskt aktiva 1,4-dihydropyridinderivat. - Google Patents
Foerfarande foer framstaellning av terapeutiskt aktiva 1,4-dihydropyridinderivat. Download PDFInfo
- Publication number
- FI79103B FI79103B FI832648A FI832648A FI79103B FI 79103 B FI79103 B FI 79103B FI 832648 A FI832648 A FI 832648A FI 832648 A FI832648 A FI 832648A FI 79103 B FI79103 B FI 79103B
- Authority
- FI
- Finland
- Prior art keywords
- formula
- methyl
- alkyl
- compounds
- reacted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Manufacture Of Tobacco Products (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (4)
1 R 2 R °2C>V^\/C02R jl I VIII H C NCH--0-Y-NH J H ^ z 30 där R, R1, R2 och Y betecknar samma som ovan, omsätts med N,N-dimetylformamidazin, varvid man erhäller sädana föreningar med formeln (I), väri X är en 1,2,4-triazolylgrupp, 35 eller 57 7 9 1 03 e) en förening med formeln (IX) pl°2C C°ip2 XX H3C^ 53 CH2-0-Y-CN där R, R1 , R2 och Y betecknar sanuna sodi ovan, omsätts med tri-n-butyltenn-azid, varvid man erhäller sädana föreningar 10 med formeln (I), väri X är en 5-tetrazolylring, och de erhällna föreningarna eventuellt alkyleras eller omsätts med klorformiat eller alkylhalogenalkanoat, varvid man erhäller sädana föreningar med formeln (I), väri X är substituerad med en Cx-C4-alkylgrupp eller gruppen 15 (CH2 )mC02 (Cx-C4-alkyl), där m är 0 eller 1, och estrarna eventuellt hydrolyseras eller omsätts med ammoniak, varvid man erhäller sädana föreningar med formeln (I), väri X är substituerad med gruppen (CH2)nC02H eller (CH2 )B C0NH2 , eller 20 f) en förening med formeln (X) r1°2C0^><\/' C°2r2 T T x
25 H3C' „ CH2-0-Y-C^S
25 NH2 där R, R1, R2 och Y betecknar samma som ovan, omsätts med en förening med formeln 30 hal-CH„-C^ YT 2 --Q XI där hai är halogen och Q är Cj-C4-alkyl eller C02 alkyl, varvid man erhäller sädana föreningar med formeln 35 (I), väri X är en grupp med formeln 58 7 9 1 03 N-f'Q XJ 5 och Q betecknar samma som ovan, och sädana föreningar, väri Q är C02(Cx-C4-alkyl), eventuellt omsätts med amrao-niak, varvid man erhäller sädana föreningar, väri X är substituerad med gruppen CONH2, eller g) en förening med formeln (XIII) 10 XX H3C h CH2-0-Y-C0NHNH2 15 där R, R1 , R2 och Y betecknar samma som ovan, omsätts med 2-metyl-isotiourea, varvid man erhäller sädana föreningar med formeln (I), väri X är 3-amino-l,2,4, 5-triazol-5-yl, 20 eller h) en förening med formeln (VIII) omsätts med hexahydro-2,4,6-trimetyl-s-triazin, varvid man erhäller sädana föreningar med formeln (I), väri X är 2,4,5-trime-tyl-( lH)imidazol-l-yl, eller med etyl-2-amino-2-cyanacetat 25 och trimetylformiat, varvid man erhäller sädana föreningar med formeln (I), väri X är 5-amino-4-etoxikarbonylimidazol- 1-yl, eller i) en förening med formeln (XIV) 30 r1°2Cv!><>02R2 xX H3c h CH2-0-Y-C0NHNHC0CH3 59 79103 där R, R1 , R2 , Q och Y betecknar sanana som ovan, omsätts med fosforpentoxid, varvid man erhäller sädana föreningar med formeln (I), väri X är 1,3,4-oxadiazol-l-yl, eller med p-metoxifenyltionofosfin, varvid man erhäller sädana 5 föreningar, väri X är 1,3,4-tiadiazol-2-yl, eller j) en förening med formeln (XV) r1°2C'V^><V/ C°2R . XX 1{2>C CH -O-Y-CONHNHC H ^nh2 där R, R1, R2 och Y betecknar samma som ovan, omsätts med 15 fosforoxiklorid, varvid man erhäller sädana föreningar med formeln (I), väri X är 5-amino-l,3,4-tiadiazol-2-yl, eller k) en förening med formeln (VIII) omsätts med hexan- 2,5-dion, varvid man erhäller sädana föreningar med formeln 20 (I), väri X är 2,5-dimetylpyrrol-l-yl; och om sä önskas, överförs den erhällna föreningen i varje fall i ett farmaceutiskt godtagbart syaradditions-salt.
1 JJ 1 h3c^ l Xch2-o-y-x 10 där R är mono- eller diklorfenyl, R1 och R2 betecknar C1-C4-alkyl, Y är - (CH2 )n -, CH2CH(CH3)- eller CH2C(CH3)2-, X är en pyridyl-, pyrrolyl-, imidazolyl-, triazolyl-, 15 tetrazolyl-, tiazolyl-, tiadiazolyl- eller oxadiazolylring, som eventuellt bär en tili tre av följande substituenter: C, -C4 -alkyl, fenyl, bensyl, N(R3 )2 , (CH2)bC02H, (CH2)„C02-(C3-C4-alkyl) eller (CH2 )BC0N(R3 )2 , i vilka varje R3 obe-roende av varandra är väte eller C1-C4-alkyl, och 20 m är 0 eller 1, och n är 1 - 3, dä X är bunden medelst ringens kolatom, eller 2 eller 3, dä X är bunden medelst ringens kväveatom, och farmaceutiskt godtagbara syraaddiotionssalter därav, kännetecknat därav, att 25 a) föreningarna med följande formeln omsätts med varandra 1 coor2 R 00C H \ / CH C \ Z (III) 30 -k (II) H3C NH2 of CH2-0-Y-X vilka formler R, R1 , R2 , X och Y betecknar sanuna som ovan, eller 2 b) föreningar med följande formler omsätts med 3 5 varandra 56 791 03 R COOR2 r1°°c ch chX II J ^ och / \ ch3^^o ch2-o-y-x 5 1Ί (V) (VI) eller c) en azid med formeln (VII) H R 10 r1°2C\><C/ C02r2 1 jf VI1 h3c CH2-0-Y-N3 där R, R1 , R2 och Y betecknar sanuna som ovan, omsätts med 15 en Cx-C4-alkylester av acetylendikarboxylsyra eller pro-piolsyra, varvid man erhäller sädana föreningar med formeln (I), väri X är en 1,2,3-triazolgrupp som är substltuerad med gruppen C02 (¢^ -C4 -alkyl), och de erhällna föreningarna eventuellt omsätts med koncentrerad ammoniumhydroxid, eller 20 de hydrolyseras eller dekarboxyleras, varvid man erhäller sädana föreningar med formeln (I), väri X är en 1,2,3-triazolylgrupp som är substituerad med karbamoyl eller karboxyl eller är osubstltuerad, eller d) en amin med formeln (VIII) 25
1. Förfarande för framställning av terapeutiskt aktiva 1,4-dihydropyridinderivat med formeln (I) 5 HN.R R1OOC COOR2
2. Förfarande enligt patentkravet 1, känne-25 tecknat därav, att R1 och Rz är CH3 eller C2 H5 och Y är - (CH2 )2 - .
3. Förfarande enligt patentkravet 1, känne-tecknat därav, att X är 2,4,5-trimetyl-l-imidazolyl, 6-dimetylamino-3-pyridyl, l-metyl-2-imidazolyl, 1,2,3-flH)- 30 triazol-l-yl, 4-karbamoyl-l,2,3-(lH)-triazol-l-yl, 3-amino- l,2,3-triazol-5-yl, 5-amino- eller 5-metyl-l,3,4-tiadiazol- 2- yl, 5-metyl-l,3,4-oxadiazol-2-yl eller 1- eller 2-metyl-eller 1- eller 2-karbamoylmetyl-tetrazol-5-yl.
4. Förfarande enligt patentkravet 1, känne-35 tecknat därav, att man framställer 4-(2-klorfenyl)- 3- etoxikarbonyl-5-metoxikarbonyl-6-metyl-2-[2-(2,4,5-trimetyl-l-imidazolyl )etoximetyl]-1,4-dihydropyridin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8221214 | 1982-07-22 | ||
GB8221214 | 1982-07-22 |
Publications (4)
Publication Number | Publication Date |
---|---|
FI832648A0 FI832648A0 (fi) | 1983-07-20 |
FI832648A FI832648A (fi) | 1984-01-23 |
FI79103B true FI79103B (fi) | 1989-07-31 |
FI79103C FI79103C (sv) | 1989-11-10 |
Family
ID=10531838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI832648A FI79103C (sv) | 1982-07-22 | 1983-07-20 | Förfarande för framställning av terapeutiskt aktiva 1,4-dihydropyridin derivat. |
Country Status (25)
Country | Link |
---|---|
US (1) | US4616024A (sv) |
EP (1) | EP0100189B1 (sv) |
JP (1) | JPS5942380A (sv) |
KR (1) | KR840005425A (sv) |
AT (1) | ATE20064T1 (sv) |
AU (1) | AU542962B2 (sv) |
CA (1) | CA1248961A (sv) |
CS (1) | CS235334B2 (sv) |
DD (1) | DD211340A5 (sv) |
DE (1) | DE3363743D1 (sv) |
DK (1) | DK333683A (sv) |
ES (1) | ES8504126A1 (sv) |
FI (1) | FI79103C (sv) |
GR (1) | GR78880B (sv) |
HU (1) | HU190725B (sv) |
IE (1) | IE55797B1 (sv) |
IL (1) | IL69284A (sv) |
NO (1) | NO832632L (sv) |
NZ (1) | NZ204964A (sv) |
PH (1) | PH30061A (sv) |
PL (1) | PL139905B1 (sv) |
PT (1) | PT77072B (sv) |
SU (1) | SU1279528A3 (sv) |
YU (1) | YU156783A (sv) |
ZA (1) | ZA835310B (sv) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE20064T1 (de) * | 1982-07-22 | 1986-06-15 | Pfizer | Anti-ischaemische und antihypertensive dihydropyridin-derivate. |
US4572908A (en) * | 1982-12-21 | 1986-02-25 | Pfizer Inc. | Dihydropyridines |
US4568677A (en) * | 1983-07-23 | 1986-02-04 | Pfizer Inc. | 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents |
GB8401288D0 (en) * | 1984-01-18 | 1984-02-22 | Pfizer Ltd | Therapeutic agents |
GB8412208D0 (en) * | 1984-05-12 | 1984-06-20 | Pfizer Ltd | Quinolone inotropic agents |
GB8414518D0 (en) * | 1984-06-07 | 1984-07-11 | Pfizer Ltd | Therapeutic agents |
DE3567460D1 (en) * | 1984-06-07 | 1989-02-16 | Pfizer Ltd | Dihydropyridines |
GB8415386D0 (en) * | 1984-06-15 | 1984-07-18 | Pfizer Ltd | Therapeutic agents |
GB8421039D0 (en) * | 1984-08-17 | 1984-09-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
GR851819B (sv) * | 1984-08-17 | 1985-11-26 | Wyeth John & Brother Ltd | |
GB8601382D0 (en) * | 1986-01-21 | 1986-02-26 | Pfizer Ltd | Dihydropyridine antiischaemic & antihypertensive agents |
EP0225175A3 (en) * | 1985-11-28 | 1988-12-28 | FISONS plc | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof |
DE3601196A1 (de) * | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-dihydropyridine |
GB8602518D0 (en) * | 1986-02-01 | 1986-03-05 | Wyeth John & Brother Ltd | 1 4-dihydropyridines |
GB8620880D0 (en) * | 1986-08-29 | 1986-10-08 | Pfizer Ltd | Therapeutic agents |
NO874194L (no) * | 1986-11-07 | 1988-05-09 | Pfizer Ltd | Fremgangsmaate ved fremstilling av dihydro-pyridinderivater |
GB8712747D0 (en) * | 1987-05-30 | 1987-07-01 | Pfizer Ltd | Therapeutic agents |
MY104933A (en) | 1987-09-30 | 1994-07-30 | Pfizer Ltd | Platelet activating factor antagonists |
GB2233974A (en) * | 1989-07-22 | 1991-01-23 | Pfizer Ltd | Dihydropyridine antiinflammatory agent |
US5739333A (en) * | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
US5977369A (en) * | 1995-12-28 | 1999-11-02 | Napp Technologies, Inc. | Process to prepare dihydropyridine and derivatives thereof |
IT1283793B1 (it) * | 1996-08-23 | 1998-04-30 | Lusochimica Spa | Processo per la preparazione di diidropiridine |
IT1310933B1 (it) | 1999-11-16 | 2002-02-27 | Luigi Benatti | Macchina multifunzionale per il monitoraggio ed il controllo diterapie locoregionali in oncologia. |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2248150A1 (de) * | 1972-09-30 | 1974-04-04 | Bayer Ag | Dihydropyridinpolyester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
US3946028A (en) * | 1972-09-30 | 1976-03-23 | Bayer Aktiengesellschaft | 2,3,5,6-Tetracarboxy-4-pyridyl-1,4-dihydropyridine derivatives |
US3943140A (en) * | 1972-09-30 | 1976-03-09 | Bayer Aktiengesellschaft | 2,3,5,6-Tetracarboxy-1,4-dihydropyridine derivatives |
US3946027A (en) * | 1972-09-30 | 1976-03-23 | Bayer Aktiengesellschaft | 3,5,6-Tricarboxy-4-pyridyl-1,4-dihydropyridine derivatives |
GB1552911A (en) * | 1975-07-02 | 1979-09-19 | Fujisawa Pharmaceutical Co | 1,4 dihydropyridine derivatives and the preparation thereof |
DE2658183A1 (de) * | 1976-12-22 | 1978-07-06 | Bayer Ag | In 2-position substituierte 1,4- dihydropyridin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
US4177278A (en) * | 1977-04-05 | 1979-12-04 | Bayer Aktiengesellschaft | 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use |
US4307103A (en) * | 1978-09-08 | 1981-12-22 | Fujisawa Pharmaceutical Co., Ltd. | Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same |
JPS5547656A (en) * | 1978-09-29 | 1980-04-04 | Dainippon Pharmaceut Co Ltd | 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative |
SE7910521L (sv) * | 1979-12-20 | 1981-06-21 | Haessle Ab | Nya 2-metyl-6-substituerade-4-(2,3-disubstituerad fenyl)-1,4-dihydropyridin-3,5-diestrar med hypotesiva egenskaper, samt forfarande for deras framstellning, och farmaceutiska beredningar innehallande desamma |
FR2472567A1 (fr) * | 1979-12-28 | 1981-07-03 | Cerm Cent Europ Rech Mauvernay | Ethers de 1- (2-propynyloxy)-2-amino-3-propanol, leur preparation et leur application en therapeutique |
CS228917B2 (en) * | 1981-03-14 | 1984-05-14 | Pfizer | Method of preparing substituted derivatives of 1,4-dihydropyridine |
JPS57175166A (en) * | 1981-04-23 | 1982-10-28 | Banyu Pharmaceut Co Ltd | Carbamoyloxyalkyl-1,4-dihydropyridine derivative and its preparation |
NZ201395A (en) * | 1981-07-30 | 1987-02-20 | Bayer Ag | Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines |
ATE20064T1 (de) * | 1982-07-22 | 1986-06-15 | Pfizer | Anti-ischaemische und antihypertensive dihydropyridin-derivate. |
-
1983
- 1983-07-18 AT AT83304150T patent/ATE20064T1/de not_active IP Right Cessation
- 1983-07-18 DE DE8383304150T patent/DE3363743D1/de not_active Expired
- 1983-07-18 EP EP83304150A patent/EP0100189B1/en not_active Expired
- 1983-07-19 ES ES524236A patent/ES8504126A1/es not_active Expired
- 1983-07-19 GR GR71971A patent/GR78880B/el unknown
- 1983-07-19 NO NO832632A patent/NO832632L/no unknown
- 1983-07-19 SU SU3618704A patent/SU1279528A3/ru active
- 1983-07-20 FI FI832648A patent/FI79103C/sv not_active IP Right Cessation
- 1983-07-20 IL IL69284A patent/IL69284A/xx unknown
- 1983-07-20 DK DK333683A patent/DK333683A/da not_active Application Discontinuation
- 1983-07-20 NZ NZ204964A patent/NZ204964A/en unknown
- 1983-07-21 DD DD83253282A patent/DD211340A5/de unknown
- 1983-07-21 CS CS835483A patent/CS235334B2/cs unknown
- 1983-07-21 KR KR1019830003355A patent/KR840005425A/ko not_active Application Discontinuation
- 1983-07-21 IE IE1713/83A patent/IE55797B1/en not_active IP Right Cessation
- 1983-07-21 AU AU17165/83A patent/AU542962B2/en not_active Ceased
- 1983-07-21 ZA ZA835310A patent/ZA835310B/xx unknown
- 1983-07-21 PT PT77072A patent/PT77072B/pt unknown
- 1983-07-21 YU YU01567/83A patent/YU156783A/xx unknown
- 1983-07-21 HU HU832575A patent/HU190725B/hu unknown
- 1983-07-21 CA CA000432928A patent/CA1248961A/en not_active Expired
- 1983-07-21 PL PL1983243130A patent/PL139905B1/pl unknown
- 1983-07-22 JP JP58134243A patent/JPS5942380A/ja active Granted
- 1983-07-22 PH PH29270A patent/PH30061A/en unknown
-
1985
- 1985-02-21 US US06/704,103 patent/US4616024A/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI79103B (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 1,4-dihydropyridinderivat. | |
EP0323841B1 (en) | Substituted pyrrole, pyrazole and triazole angiotensin ii antagonists | |
US5081127A (en) | Substituted 1,2,3-triazole angiotensin II antagonists | |
JPH09504039A (ja) | 抗腫瘍剤または抗ウイルス剤としてのジスタマイシンaアナログ | |
US5332820A (en) | Dibenzobicyclo(2.2.2) octane angiotensin II antagonists | |
CZ283018B6 (cs) | Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi | |
JP2000309579A (ja) | 新規アミノトリアゾール化合物、これらの製造方法及びこれらを含む医薬組成物 | |
EA003603B1 (ru) | N-[(замещенное пятичленное ди- или триазадиненасыщенное кольцо) карбонил] гуанидиновые производные для лечения ишемии | |
US20200308165A1 (en) | Compounds as Ras Inhibitors and Use Thereof | |
FI79104C (sv) | Förfarande för framställning av ett nytt terapeutiskt användbart dihyd ropyridinderivat. | |
CZ20021591A3 (cs) | 5-Aryl-1H-1, 2, 4-triazoly jakoľto inhibitory cyklooxygenasy-2 a farmaceutické kompozice obsahující tyto sloučeniny | |
US4515799A (en) | Dihydropyridine anti-ischaemic and antihypertensive agents | |
EP0568437B1 (en) | Antidepressant 3-Halophenylpiperazinyl-propyl Derivatives of Substituted Triazolones and Triazoldiones | |
IE58443B1 (en) | Dihydropyridine anti-ischaemic and antihypertensive agents | |
US5189048A (en) | Substituted 1,2,3 triazole angiotensin II antagonists | |
CA2194563A1 (en) | Anti-helicobacter heterocyclic derivatives of azolones | |
US5093346A (en) | Substituted 1,2,4-triazole angiotensin II antagonists | |
US5043349A (en) | Substituted pyrrole angiotensin II antagonists | |
US4548935A (en) | Dihydropyridine anti-ischaemic and anti-hypertensive agents, compositions and use | |
US5315013A (en) | Substituted pyrazole angiotensin II antagonists | |
HU206343B (en) | Process for producing 1,2-benzizoxazol- and 1,2-benzizothiazol derivatives and pharmaceutical compositions containing them | |
EP0229922B1 (en) | Novel 2,2'-bi-1h-imidazoles | |
CA2007401A1 (fr) | Derives des bisarylalcenes, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
EP0329070A1 (en) | Cardiotonic alkanoyl and aroyl oxazolones | |
US5147863A (en) | 2,2'-bi-1H-imidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |
Owner name: PFIZER CORPORATION |